Literature DB >> 7912402

Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile.

A M Gonzalez1, D Walther, A Pazos, G R Uhl.   

Abstract

The human vesicular monoamine transporter (hSVMT) cDNA predicts a protein of 515 amino acids that shares 92% amino acid identity with the rat cDNA. Northern analyses reveal expression of 4.3 kb SVMT mRNAs in rat hypothalamus, midbrain and brainstem, a 3 kb hSVMT mRNA in human brainstem and a 4.8 kb hSVMT mRNA in human hypothalamus. In situ hybridization documents significant SVMT expression in human nigra compacta neurons and in rat hypothalamic neurons whose distribution patterns are identical to those previously reported to display histaminergic markers. COS cell hSVMT expression yielded nanomolar affinities for tetrabenazine and reserpine, micromolar affinities for haloperidol, GBR12909, serotonin, mazindol, nomifensin and d-amphetamine, while dopamine, epinephrine, norepinephrine and histamine each displayed millimolar affinities. These observations extend the pharmacological characterization of hSVMT and studies of its distribution, and indicate likely physiological roles for SVMT in packaging monoamine transmitters including histamine.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7912402     DOI: 10.1016/0169-328x(94)90050-7

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  10 in total

1.  An in vivo microdialysis study of striatal 6-[18F]fluoro-L-m-tyrosine metabolism.

Authors:  S Jordan; K S Bankiewicz; J L Eberling; H F VanBrocklin; J P O'Neil; W J Jagust
Journal:  Neurochem Res       Date:  1998-04       Impact factor: 3.996

2.  Reserpine- and tetrabenazine-sensitive transport of (3)H-histamine by the neuronal isoform of the vesicular monoamine transporter.

Authors:  J D Erickson; L E Eiden; M K Schafer; E Weihe
Journal:  J Mol Neurosci       Date:  1995       Impact factor: 3.444

Review 3.  How addictive drugs disrupt presynaptic dopamine neurotransmission.

Authors:  David Sulzer
Journal:  Neuron       Date:  2011-02-24       Impact factor: 17.173

4.  Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter.

Authors:  J D Erickson; M K Schafer; T I Bonner; L E Eiden; E Weihe
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

5.  Vmat2 heterozygous mutant mice display a depressive-like phenotype.

Authors:  Masato Fukui; Ramona M Rodriguiz; Jiechun Zhou; Sara X Jiang; Lindsey E Phillips; Marc G Caron; William C Wetsel
Journal:  J Neurosci       Date:  2007-09-26       Impact factor: 6.167

6.  Association of VMAT2 gene polymorphisms with alcohol dependence.

Authors:  Christoph Fehr; Daniel Sommerlad; Thomas Sander; Ion Anghelescu; Norbert Dahmen; Armin Szegedi; Christiana Mueller; Peter Zill; Michael Soyka; Ulrich W Preuss
Journal:  J Neural Transm (Vienna)       Date:  2013-03-17       Impact factor: 3.575

7.  Selective genetic disruption of dopaminergic, serotonergic and noradrenergic neurotransmission: insights into motor, emotional and addictive behaviour.

Authors:  Elsa Isingrini; Lea Perret; Quentin Rainer; Sara Sagueby; Luc Moquin; Alain Gratton; Bruno Giros
Journal:  J Psychiatry Neurosci       Date:  2016-04       Impact factor: 6.186

8.  Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems.

Authors:  F S Hall; K Itokawa; A Schmitt; R Moessner; I Sora; K P Lesch; G R Uhl
Journal:  Neuropharmacology       Date:  2013-08-24       Impact factor: 5.250

9.  Tetrabenazine in the treatment of Huntington's disease.

Authors:  Diana Paleacu
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

10.  Autoreceptor control of serotonin dynamics.

Authors:  Janet Best; William Duncan; Farrah Sadre-Marandi; Parastoo Hashemi; H Frederik Nijhout; Michael Reed
Journal:  BMC Neurosci       Date:  2020-09-23       Impact factor: 3.288

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.